NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Wednesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 3.1 %

NASDAQ NURO opened at $4.05 on Wednesday. The stock has a market capitalization of $8.26 million, a PE ratio of -0.88 and a beta of 2.20. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The company has a 50 day moving average price of $4.00 and a two-hundred day moving average price of $3.87.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same period in the previous year, the firm posted ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.